Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $9

Benzinga · 4d ago
Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $10 to $9.